Stay updated on Apremilast in Nummular Eczema Clinical Trial
Sign up to get notified when there's something new on the Apremilast in Nummular Eczema Clinical Trial page.

Latest updates to the Apremilast in Nummular Eczema Clinical Trial page
- Check4 days agoChange DetectedA dedicated Locations section was added, listing Bavaria as a study site, and the page revision updated to v3.3.3. The older grouping 'Bavaria Locations' was removed along with the HHS Vulnerability Disclosure link.SummaryDifference0.2%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedThe page now displays a new revision header 'Revision: v3.3.2' replacing the previous 'Revision: v3.2.0'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check40 days agoChange DetectedThe government funding status notice has been removed from the page. The notice previously informed users about potential delays in updates and responses due to funding lapses.SummaryDifference0.4%

- Check54 days agoChange DetectedThe screenshots show only minor visual/layout adjustments; the core study details appear unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check83 days agoChange DetectedThe page is updated to v3.2.0 and adds a government operating-status notice, replacing the previous v3.1.0 reference.SummaryDifference4%

- Check90 days agoChange DetectedPage now shows revision to v3.1.0 and removes several drug-safety-related topics (Drug Safety, Counterfeit Drugs, Pharmaceutical Preparations, Substandard Drugs) from the content, indicating a shift away from those topics while adding a new version.SummaryDifference0.4%

Stay in the know with updates to Apremilast in Nummular Eczema Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Apremilast in Nummular Eczema Clinical Trial page.